Screener
Agios Pharmaceuticals AGIO Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from maturities and sales of marketable securities | 508,256 | 508,894 |
| Payments associated with license agreement | (25,000) | (10,000) |
| Purchases of property and equipment | (1,981) | (1,641) |
| Net cash provided by investing activities | 181,522 | 191,553 |
| Financing activities | ||
| Net proceeds from stock option exercises and employee stock purchase plan | 5,227 | 1,684 |
| Net cash provided by financing activities | 5,227 | 1,684 |
| Net change in cash and cash equivalents | 10,517 | 4,624 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's investing cash flow?
- Agios Pharmaceuticals (AGIO) reported investing cash flow of $40.21M in Q2 2026.
- How has Agios Pharmaceuticals's investing cash flow changed year-over-year?
- Agios Pharmaceuticals's investing cash flow decreased by 49.1% year-over-year, from $78.97M to $40.21M.
- What is the long-term trend for Agios Pharmaceuticals's investing cash flow?
- Over 2 years (2022 to 2025), Agios Pharmaceuticals's investing cash flow has grown at a 24.5% compound annual growth rate (CAGR), from $243.26M to $377.18M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Agios Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude